Potential Parkinson’s Treatment, DNL201, Safe and Well-Tolerated in Phase 1 Study, Denali Says
Denali Therapeutics’ reports that its investigational compound for Parkinson’s disease, DNL201, was found to be safe and well-tolerated by healthy individuals in a Phase 1 clinical trial. The company is planning to advance the compound into a Phase 1b study in patients, a press release states. DNL201 is an inhibitor…